Meeting US Rules on Clinical Trial Deviations
This article was originally published in SRA
Nancy J Stark explains how the US Food and Drug Administration and institutional review boards define violations and deviations in medical device clinical trials.
You may also be interested in...
Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients
As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.
With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.